Vendor Intelligence Report: Chimera Peptides
Published 12 Nov 2026. 28-page investigative report on who is behind Chimera Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Chimera Peptides is a narrow-product lab success with a wider operational problem. Across 28 Finnrick lab tests, Chimera has 27 passes and 1 fail — a 96% overall pass rate. The signal is not evenly transferable across the store: Retatrutide is the standout; Tirzepatide’s lone fail is dosing-relevant overfill, made more visible under stricter grading; GHK-Cu is positive but thin.
The investigation treats chimera.is as the current official storefront, but the buying path is polluted. The legacy no-hyphen domain is on registrar hold, a former Lovable checkout now shows a Trust & Safety takedown, and a live hyphenated WooCommerce lookalike hotlinks Chimera COA images while using different payment and shipping cues.
Accountability is unresolved. The site publishes policies, COAs, referral terms and a vendor letter describing a leadership disruption, but it does not name a legal counterparty, address, beneficial owner or batch-release authority — a disclosure gap, not proof such personnel do not exist; the Florida LLC lead could not be tied to the current vendor in the public records reviewed. Payment and support terms are buyer-unfriendly: crypto or opaque middleman rails, a 25-day support threshold, arbitration language and route-specific US-shipping contradictions. Chimera looks most defensible only for the tested products, especially Retatrutide, after domain verification and lot-level independent testing.
Inside the full report:
- Per-product Finnrick charts and methodology-divergence exhibits for the three tested products
- Domain-authenticity map of chimera.is, the held legacy domain, the hyphen clone and lookalikes
- Corporate-record review of the Florida LLC lead and related peptide/wellness entities
- Payment-policy analysis covering BTC wallet activity, middleman terms, support rules and arbitration language
- Complaint and reputation review from Peptide Critic, Trustpilot, Reddit and K-HOLE
- Open-lead index for Janoshik verification, Telegram/X limits, payee identity and clone-operator tracing
Risk assessment
- Copycat / brand-confusion risk — high: Vendor claims chimera.is is official, but chimera-peptides.com and chimerapeptidez.com are live/lookalike flows, one hotlinks chimera.is COAs and buyers report advance-fee losses.
- Fulfillment, payment and support-continuity risk — high: International-only shipping, crypto/middleman payments, 25-day reship threshold, dead Discord/broadcast Telegram and unresolved non-delivery complaints.
- Accountability / legal-counterparty opacity risk — medium: chimera.is discloses no legal entity, address, UBO or QA release authority; Florida LLC link is not established.
- Tirzepatide fill-accuracy risk — medium: Tirzepatide has 9 tests, 8 pass / 1 fail; the failed 30 mg vial measured 32.7 mg, 108.9% of label, and the vendor described a 10% overfill target.
- Untested-catalog and batch-traceability risk — medium: Products outside Retatrutide, Tirzepatide and GHK-Cu lack Finnrick support, and the vendor says vials lack lot numbers with cap color used as a proxy.
- Unresolved GLP-1 provenance allegation risk — medium: A K-HOLE-published Janoshik image for an alleged Chimera GLP-1 sample reported semaglutide, tirzepatide and retatrutide not detected, but chain of custody remains unresolved.